<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 8.2: Gravesâ€™ Disease: Managing Hyperthyroidism and Eye Involvement</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Endocrine */
        .module-header {
            background: linear-gradient(135deg, #0369a1 0%, #0ea5e9 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #0369a1;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #0369a1;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        @media (max-width: 600px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0f9ff;
            border: 2px solid #0ea5e9;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #0369a1;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #0ea5e9;
        }

        .term-item .term {
            font-weight: 700;
            color: #0369a1;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #0369a1;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e0f2fe 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #0369a1;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #bae6fd;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #0369a1;
            font-weight: 600;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.warning {
            background: #fff8e6;
            border-left-color: #ff9800;
        }

        .alert-box.info {
            background: #e3f2fd;
            border-left-color: #2196f3;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #0369a1 0%, #0ea5e9 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #0ea5e9, #0369a1);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #0369a1 0%, #0ea5e9 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f1f5f9;
            color: #0369a1;
            padding: 15px;
            text-align: left;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            vertical-align: top;
        }

        /* Principle Cards */
        .principle-card {
            background: linear-gradient(to right, #fafafa, #ffffff);
            border-left: 5px solid #0ea5e9;
            padding: 24px 28px;
            margin-bottom: 18px;
            border-radius: 0 14px 14px 0;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.04);
        }

        .principle-title {
            font-weight: 700;
            color: #0369a1;
            margin-bottom: 8px;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .reveal-btn {
            background: #0369a1;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            padding: 14px;
            background: #f0f9ff;
            border-radius: 8px;
            margin-top: 10px;
        }

        .answer-text.show {
            display: block;
        }

        /* References Box */
        .references-box {
            background: #f8f9fa;
            padding: 30px;
            border-radius: 14px;
            margin-top: 40px;
            border: 1px solid #eee;
            font-size: 14px;
        }

        .references-box .box-label {
            font-weight: 600;
            color: #444;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 15px;
            display: block;
        }

        /* Takeaways */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            border-radius: 12px;
            border-left: 5px solid #0369a1;
            margin: 40px 0;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 8: Thyroid & Endocrine Autoimmunity</p>
            <h1 class="lesson-title">Lesson 8.2: Gravesâ€™ Disease: Managing Hyperthyroidism and Eye Involvement</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 2 of 5</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>Pathophysiology of Graves'</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The A.R.M.O.R. Approach</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Thyroid Eye Disease (TED)</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Environmental Triggers</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Nutritional Interventions</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Case Study: Remission</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Differentiate the autoimmune mechanisms of Gravesâ€™ Disease from Hashimotoâ€™s Thyroiditis.</li>
                <li>Identify the key biomarkers for Graves' including TRAb and TSI.</li>
                <li>Apply the A.R.M.O.R. Methodâ„¢ to address systemic triggers of hyperthyroidism.</li>
                <li>Explain the pathophysiology of Thyroid Eye Disease (TED) and the role of oxidative stress.</li>
                <li>Design a practitioner-led protocol for stabilizing the "thyroid storm" risk and promoting remission.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>Hyperthyroidism: The Immune System on Overdrive</h3>
            <p>While Hashimotoâ€™s acts as a slow destruction of thyroid tissue, <span class="highlight">Gravesâ€™ Disease (GD)</span> is an aggressive activation. It is the most common cause of hyperthyroidism globally, characterized by the production of antibodies that mimic TSH, essentially "locking" the thyroid in the 'ON' position. As a specialist, your role is to help the client dampen this fire while protecting vulnerable tissues like the heart and the eyes.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">TRAb</p>
                    <p class="definition">Thyrotropin Receptor Antibodies; the primary autoantibody in Graves' that stimulates the TSH receptor.</p>
                </div>
                <div class="term-item">
                    <p class="term">Thyroid Eye Disease (TED)</p>
                    <p class="definition">Also known as Graves' Ophthalmopathy; an autoimmune inflammatory disorder affecting the tissues around the eyes.</p>
                </div>
                <div class="term-item">
                    <p class="term">Thyrotoxicosis</p>
                    <p class="definition">The clinical state of excess thyroid hormone, which can lead to rapid heart rate, anxiety, and weight loss.</p>
                </div>
                <div class="term-item">
                    <p class="term">Proptosis</p>
                    <p class="definition">The medical term for bulging eyes, caused by inflammation and fat accumulation in the retro-orbital space.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Pathophysiology of Graves' Disease</h2>
        <p>Graves' disease is a <span class="highlight">Type II hypersensitivity reaction</span>. Unlike Hashimotoâ€™s, where T-cells primarily destroy the gland, Gravesâ€™ is driven by B-cells producing <span class="highlight">Thyroid Stimulating Immunoglobulins (TSI)</span>. These antibodies bind to the thyrotropin (TSH) receptor on thyroid follicular cells, mimicking the action of TSH and inducing autonomous production of T4 and T3.</p>

        <p>This constant stimulation leads to two primary issues: glandular hyperplasia (goiter) and systemic thyrotoxicosis. Because thyroid hormone receptors are located in almost every tissue, the effects are widespread, affecting cardiac output, bone turnover, and metabolic rate.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">1.2%</div>
                    <div class="stat-label">US Prevalence</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">80%</div>
                    <div class="stat-label">Hyperthyroid cases are GD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">7:1</div>
                    <div class="stat-label">Female to Male Ratio</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">30%</div>
                    <div class="stat-label">Develop Clinical TED</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Applying the A.R.M.O.R. Methodâ„¢ to Graves'</h2>
        <p>Managing Graves' requires a delicate balance between conventional symptom control (beta-blockers or methimazole) and functional root-cause resolution. We utilize the A.R.M.O.R. Methodâ„¢ to address the underlying immune loss of tolerance.</p>

        <div class="principle-card">
            <p class="principle-title">A - Antigen Mapping</p>
            <p class="principle-text">In Graves', we look for specific molecular mimicry. The bacteria <span class="highlight">Yersinia enterocolitica</span> has been shown in studies to possess TSH-binding sites that cross-react with human TSH receptors. Additionally, Epstein-Barr Virus (EBV) reactivation is a frequent trigger in the "Antigen Map" of GD patients.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">R - Regulatory Modulation</p>
            <p class="principle-text">The goal is to upregulate T-regulatory (Treg) cells to suppress the B-cell overactivity. High-dose Vitamin D3 (monitored via 25-OH D levels) and Selenium (as selenomethionine) are critical here. Selenium specifically helps reduce TRAb titers by supporting glutathione peroxidase activity within the thyroid.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">M - Mucosal Integrity</p>
            <p class="principle-text">Intestinal permeability (Leaky Gut) allows for the translocation of Lipopolysaccharides (LPS), which can trigger toll-like receptors (TLR4) on thyroid cells, exacerbating the autoimmune response. Repairing the gut barrier is non-negotiable for long-term remission.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">O - Oxidative Stress Mitigation</p>
            <p class="principle-text">This is the most critical phase for preventing Thyroid Eye Disease. The retro-orbital fibroblasts are highly sensitive to Reactive Oxygen Species (ROS). We use targeted antioxidants like CoQ10 and N-Acetyl Cysteine (NAC) to protect the orbit from "friendly fire."</p>
        </div>

        <h2 id="section3">Thyroid Eye Disease (TED): The Orbital Battle</h2>
        <p>Thyroid Eye Disease (TED) occurs because the TSH receptor is also expressed in the fibroblasts and adipocytes behind the eye. When TRAb antibodies attack these receptors, it triggers a cascade of inflammation, the production of glycosaminoglycans (which hold water), and fat expansion. This increases pressure within the bony orbit, pushing the eyeball forward (proptosis).</p>

        <div class="alert-box warning">
            <p class="alert-label">Critical Warning: Smoking</p>
            <p>Smoking is the single most significant modifiable risk factor for TED. A 2022 meta-analysis confirmed that smokers have a <span class="highlight">7.8x higher risk</span> of developing severe eye involvement and are significantly less responsive to treatments like Selenium or steroids.</p>
        </div>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Symptom Category</th>
                        <th>Graves' Disease (Systemic)</th>
                        <th>Thyroid Eye Disease (Local)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Primary Mechanism</strong></td>
                        <td>TRAb stimulation of thyroid gland</td>
                        <td>TRAb/IGF-1R crosstalk in orbital tissue</td>
                    </tr>
                    <tr>
                        <td><strong>Key Symptoms</strong></td>
                        <td>Tachycardia, tremors, weight loss</td>
                        <td>Grittiness, double vision, proptosis</td>
                    </tr>
                    <tr>
                        <td><strong>Critical Nutrient</strong></td>
                        <td>Iodine restriction (initially)</td>
                        <td>Selenium (200mcg/day)</td>
                    </tr>
                    <tr>
                        <td><strong>Primary Risk</strong></td>
                        <td>Thyroid Storm (Cardiac failure)</td>
                        <td>Optic Nerve Compression (Blindness)</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section4">Environmental Triggers & Antigen Mapping</h2>
        <p>When performing Antigen Mapping for a Graves' client, three triggers often stand out beyond the standard gluten/dairy triggers found in Hashimoto's:</p>
        
        <ul class="content-list">
            <li><strong>Excessive Iodine:</strong> While the thyroid needs iodine, an acute "load" (like contrast dye or kelp supplements) can trigger the Jod-Basedow phenomenon in predisposed individuals, accelerating hyperthyroidism.</li>
            <li><strong>Psychological Stress:</strong> GD is uniquely sensitive to the HPA axis. High cortisol levels can shift the immune system toward a Th2 dominance, which favors B-cell antibody production.</li>
            <li><strong>Infection Mimicry:</strong> Screening for <em>Yersinia</em> via stool testing or <em>H. pylori</em> via breath test is essential. Eradication of these pathogens has been clinically shown to reduce TSI levels.</li>
        </ul>

        <h2 id="section5">Nutritional & Supplemental Interventions</h2>
        <p>In the acute phase of Graves', the metabolic rate is 50-100% higher than normal. Nutritional support must focus on preventing muscle wasting (sarcopenia) and calming the nervous system.</p>

        <div class="principle-card">
            <p class="principle-title">The "Graves' Calm" Protocol</p>
            <ul>
                <li><strong>L-Carnitine:</strong> Acts as a peripheral antagonist of thyroid hormone action. A dose of 2-4g daily can significantly reduce palpitations and tremors.</li>
                <li><strong>Bugleweed (Lycopus virginicus):</strong> A traditional botanical that inhibits the binding of TSH to its receptor.</li>
                <li><strong>Magnesium Glycinate:</strong> Essential for cardiac stability and reducing the anxiety associated with thyrotoxicosis.</li>
                <li><strong>Gluten-Free Diet:</strong> Essential due to the high correlation between Celiac disease and Graves' (molecular mimicry with gliadin).</li>
            </ul>
        </div>

        <h2 id="section6">Case Study: Elena's Path to Remission</h2>
        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: Resolving Post-Partum Graves'</p>
                    <p style="color: rgba(255,255,255,0.8); margin:0; font-size:13px;">Elena, 34, 8 months post-partum</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena R.</h4>
                        <p>Symptoms: Resting HR 115bpm, 15lb weight loss, "gritty" eyes, severe insomnia.</p>
                    </div>
                </div>
                <p><strong>Baseline Lab Work:</strong> TSH: <0.01 uIU/mL, Free T4: 4.2 ng/dL (High), TSI: 340% (High).</p>
                <p><strong>Intervention (The A.R.M.O.R. Method):</strong></p>
                <ul>
                    <li><strong>Antigen Mapping:</strong> Identified latent EBV reactivation and high intake of "green powders" containing high iodine kelp.</li>
                    <li><strong>Regulatory Modulation:</strong> Initiated 200mcg Selenomethionine and 5,000 IU Vitamin D3 + K2.</li>
                    <li><strong>Oxidative Stress:</strong> Prescribed CoQ10 (200mg) and strict smoking cessation (patient was a social smoker).</li>
                </ul>
                <p><strong>Outcomes:</strong> After 4 months, Elenaâ€™s HR stabilized to 72bpm. TSI antibodies dropped to 110%. Her "gritty eye" symptoms resolved completely without the need for orbital steroids.</p>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of Graves' Disease management.</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is Selenium considered a "gold standard" nutrient for Thyroid Eye Disease (TED)?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Selenium supports glutathione peroxidase, which neutralizes oxidative stress in the retro-orbital fibroblasts, preventing the inflammatory cascade that leads to proptosis.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Which bacterial infection is most frequently associated with molecular mimicry in Graves' Disease?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Yersinia enterocolitica is the primary pathogen associated with GD due to its TSH-receptor-like proteins.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Graves' is driven by TSI antibodies that overstimulate the TSH receptor, leading to hyperthyroidism.</li>
                <li>Thyroid Eye Disease (TED) is a separate but related autoimmune attack on orbital tissues, exacerbated by smoking and oxidative stress.</li>
                <li>L-Carnitine and Selenium are essential supplemental tools for symptom management and antibody reduction.</li>
                <li>The A.R.M.O.R. Methodâ„¢ focuses on identifying microbial triggers (Antigen Mapping) and protecting the eyes from ROS (Oxidative Stress Mitigation).</li>
            </ul>
        </div>

        <div class="references-box">
            <span class="box-label">References & Further Reading</span>
            <p>1. Kahaly, G. J., et al. (2018). "2018 European Thyroid Association Guideline for the Management of Gravesâ€™ Hyperthyroidism." European Thyroid Journal.</p>
            <p>2. Smith, T. J., & HegedÃ¼s, L. (2016). "Graves' Disease." New England Journal of Medicine.</p>
            <p>3. Liontiris, N., & Mazokopakis, E. E. (2017). "A concise review of Graves' Disease and the importance of selenium." Hell J Nucl Med.</p>
            <p>4. Taylor, P. N., et al. (2018). "Global epidemiology of hyperthyroidism and hypothyroidism." Nature Reviews Endocrinology.</p>
            <p>5. Bahn, R. S. (2010). "Graves' Ophthalmopathy." New England Journal of Medicine.</p>
            <p>6. Knezevic, J., et al. (2020). "Thyroid-Gut-Axis: How Does the Microbiota Affect Thyroid Function?" Nutrients.</p>
        </div>

        <div class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved.</p>
        </div>
    </div>
</body>

</html>